Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03797014 · ClinicalTrials.gov registry record · Phase 4
B/F/TAF Switch Study for HIV-HBV Coinfection
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT03797014 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 28 participants.
The verdict
NCT03797014, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects enrolled will be switched from their current antiretroviral regimen to B/F/TAF will be followed on treatment for 48 weeks.
Interventions
- DRUG B/F/TAF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03797014
The ClinicalTrials.gov registry entry for NCT03797014 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which B/F/TAF is the first listed.
NCT03797014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03797014 about?
NCT03797014 is a clinical study titled "B/F/TAF Switch Study for HIV-HBV Coinfection". The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects enrolled will be switched from t...
What is the current status of trial NCT03797014?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2019-04-30. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT03797014?
The interventions under investigation include: B/F/TAF (DRUG).
Who is sponsoring clinical trial NCT03797014?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.